Amgen Articles
Stock Commentary - New York
3 March 2003
Stock Commentary - Week to Feb 10 - New York
17 February 2003
Stock commentary - week to Feb 10 - Tokyo
17 February 2003
Stock Commentary - New York
10 February 2003
Update: Biogen gets US approval for Amevive
10 February 2003
Serono sees 15%-20% growth for 2003
10 February 2003
New report sees big changes for global antibiotics market
10 February 2003
Biogen's Amevive cleared for psoriasis
10 February 2003
Amgen's mucositis drug clears Phase III trial
3 February 2003
Earnings up at Wyeth, HRT drugs sluggish
3 February 2003
J&J ordered to pay Amgen's costs in Procrit case
3 February 2003
Stock Commentary - week to Jan 20 - New York
27 January 2003
Amgen files Enbrel for spondylitis
27 January 2003
Drugmakers' success depends on effective therapeutic franchising
27 January 2003
Update - Amgen says Enbrel psoriasis trial is positive
27 January 2003
Amgen says Enbrel clears Ph III psoriasis trial
27 January 2003
Stock Commentary week to Jan 13 - New York
20 January 2003
Round-up of pharmaceutical mergers and acquisitions during 2001
13 January 2003
Amgen says appeals court confirms Epogen ruling
13 January 2003
New York Stock Commentary - 2 weeks to Dec 30
6 January 2003
XOMA/Genentech file Raptiva BLA in USA
6 January 2003
FDA filings in brief
6 January 2003
Abbott gets approval for blockbuster candidate Humira in USA
6 January 2003
TKT victory over UK Dynepo patent
5 August 2002
10 most effective US DTC television ads
5 August 2002
Only beginning for pharma/biotech alliances
29 July 2002
Stock Commentary - New York
29 July 2002
New use for Amgen's Aranesp OKed in USA
29 July 2002
Amgen announces $2B stock repurchase plan
22 July 2002
US FTC OKs Amgen/Immunex merger
22 July 2002
Cuba plans massive EPO export effort
15 July 2002
Royalty Pharma cancel Swiss IPO
24 June 2002
Pharma lobby "army" growth in 2001: study
24 June 2002
Amgen to commence $2bn stock buy-back plan
17 June 2002
Stock Commentary - New York
10 June 2002
Aranesp gets CPMP backing for two drugs
10 June 2002
Pharma-biotech alliances studied
10 June 2002
Amgen's Aranesp beats J&J's Procrit
3 June 2002
Stock Commentary - New York
3 June 2002
Stock Commentary - New York
27 May 2002
Shareholders approve Immunex/ Amgen merger
27 May 2002
Celltech/Amgen link-up on Crohn's drug
27 May 2002
InterMune acquires Amgen patent estate
20 May 2002
Stock Commentary - New York
13 May 2002
Amgen buys filgrastim rights for $137 million
13 May 2002
Stock Commentary - New York
6 May 2002
Blockbuster drug era "at crossroads"
6 May 2002
Amgen's celebrity marketing of Neulasta
29 April 2002
Clue to pathogenesis of Alzheimer's disease
15 April 2002
Novartis researchers honored by AACR
15 April 2002
No launch yet for TKT's Dynepo, says Aventis
15 April 2002
Increased pressure in biotech for future profit
15 April 2002
Zymogenetics sues Immunex over Enbrel
18 March 2002
TranXenoGen posts $4 million loss for 2001
11 March 2002
Amgen to raise $2.5 billion
4 March 2002
Stock Commentary - New York
4 March 2002
Enbrel also active in psoriasis, says study
4 March 2002
NEJM study finds more aplasia cases with J&J's Eprex
25 February 2002
Stock Commentary - New York
11 February 2002
FDA approves Amgen's new-generation filgrastim product, Neulasta
11 February 2002
Amgen gets US OK for pegfilgrastim
11 February 2002
Medarex appointment
4 February 2002
Fresenius snubs J&J in favor of Amgen
28 January 2002
Immunex' Enbrel cleared for psoriatic arthritis.
21 January 2002
Neurotech licenses Amgen's CNTF for eye diseases.
21 January 2002
Amgen forms drug discovery link with Denmark's Acadia.
21 January 2002
Tally of NCEs in 2001 lends credence to talk of R&D productivity
21 January 2002
Beth Seidenberg joins Amgen.
21 January 2002
Stock Commentary - New York
14 January 2002
Regeneron arthritis drug clears early trial
14 January 2002
Amgen planning to acquire Immunex Corp in $18 billion deal?
7 January 2002
Acadia signs small-molecule deal with Amgen
7 January 2002
Stock Commentary - New York
7 January 2002
Amgen planning to acquire Immunex Corp in $18 billion deal?
7 January 2002
Amgen confirms $16 billion bid for Immunex
7 January 2002
Amgen planning to acquire Immunex Corp in $18 billion deal?
18 December 2001
Amgen planning to acquire Immunex Corp in $18 billion deal?
14 December 2001
Amgen says pegfilgrastim as effective as filgrastim in neutropenia
13 December 2001
Amgen's epratuzumab in combo regimen for NHL
12 December 2001
Tokyo pharma stocks - week to December 10
11 December 2001
Stock Commentary - New York
6 December 2001
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
